Why edibles hit different: the discovery of the metabolite that makes eaten cannabis more potent
11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man
Bottom Line
When you eat cannabis, your liver converts THC into 11-hydroxy-THC — a metabolite with roughly 100 times higher receptor binding affinity that crosses the blood-brain barrier more efficiently, explaining why edibles feel more intense and last longer.
Why It Matters
This paper is the molecular explanation for why edibles feel different from smoking. It has direct relevance to every person who has ever had an unexpectedly intense edible experience, every emergency room visit from edible overconsumption, and every dosing guideline for oral cannabis products.
The Backstory
The story always starts the same way. Someone eats a cannabis edible — a gummy, a brownie, a chocolate bar. They wait 30 minutes and feel nothing. They eat another piece. An hour after the first dose, both hit simultaneously and the experience is nothing like smoking. It is deeper, more physical, more intense, and it lasts for hours. Some people love it. Some people end up in the emergency room.
The pharmacological reason this happens has been known since 1972. A researcher named Louis Lemberger, working at the National Institute of Mental Health, published a three-page paper in Science that identified the molecule responsible: 11-hydroxy-THC. When you eat cannabis, your liver does not just process the THC — it converts it into something more potent.
The Man Who Mapped THC Metabolism
Louis Lemberger earned both his MD and PhD in Pharmacology from Albert Einstein College of Medicine. During the Vietnam War era, he served as a Commissioned Officer in the U.S. Public Health Service at the NIH's National Institute of Mental Health — an assignment that put him at the center of the government's interest in understanding cannabis pharmacology.
In two years at NIMH, Lemberger published roughly a dozen papers on THC, many as first author, in the most prestigious journal in science. Three of them appeared in Science in rapid succession:
- 1970: The first study of THC disposition and metabolism in humans — establishing that delta-9-THC persists in plasma for more than 3 days with a half-life of 56 hours
- 1971: Differences between chronic cannabis users and naive subjects — chronic users cleared THC from blood with a half-life of 28 hours versus 57 hours in nonusers
- 1972: The 11-OH-THC paper — identifying the active metabolite that would explain why edibles feel different from smoking
In 1971, Lemberger moved to Eli Lilly in Indianapolis, where he became Director of Clinical Pharmacology. The career that followed reads like a pharmacological hall of fame: he was the first physician to administer Prozac (fluoxetine), Zyprexa (olanzapine), Cesamet (nabilone — a synthetic cannabinoid for chemotherapy nausea), Strattera (atomoxetine), and Permax (pergolide) to a human being. The man who decoded how the body processes cannabis went on to develop the world's most successful antidepressant.
The First-Pass Problem
When you smoke or vape cannabis, THC enters your lungs and passes directly into your bloodstream. Within seconds, it reaches your brain. Your liver eventually metabolizes it, but most of the initial dose hits cannabinoid receptors as delta-9-THC — the molecule in the plant.
When you eat cannabis, the path is entirely different.
The Numbers That Explain Everything
~100x
higher binding affinity at CB1 receptors. Later receptor binding studies found 11-OH-THC has a Ki of approximately 0.37 nM at the CB1 receptor, compared to roughly 35 nM for delta-9-THC. This means 11-OH-THC grabs onto the same receptor roughly 100 times more tightly. Combined with better blood-brain barrier penetration, this makes the oral metabolite substantially more potent per molecule than the parent compound.
For context, this is not a subtle difference. It is comparable to the potency gap between a regular beer and a shot of high-proof liquor — the same active ingredient, dramatically concentrated by metabolic processing.
Receptor binding data from subsequent studies; potency estimates from animal models suggest 2-7x greater psychoactive effect
Why People Get Into Trouble
The delayed onset is the practical danger of this pharmacokinetic pathway. When you smoke cannabis and it is too strong, you know within minutes. When you eat an edible that is too strong, you may not know for an hour or more — by which time many people have taken a second dose.
The same pharmacokinetics explain several other edible-specific phenomena:
- Why edible withdrawal can feel different: 11-OH-THC has a longer half-life than delta-9-THC, so it takes longer to clear the system. Regular edible users may have higher steady-state levels of the more potent metabolite.
- Why edibles feel more "body-heavy": The qualitative difference consumers report is likely related to the different receptor binding profile of 11-OH-THC versus THC.
- Why THC stays in your system so long: Lemberger's original 1972 paper showed drug and metabolites excreted for more than one week. Cannabis metabolites are lipophilic, stored in fat tissue, and released slowly.
- Why sublingual products hit faster than edibles: THC absorbed under the tongue enters the bloodstream directly, partially bypassing first-pass liver metabolism. Less 11-OH-THC is formed, so the experience is somewhere between smoking and eating.
The Broader Legacy
Lemberger's three papers in Science (1970, 1971, 1972) established cannabinoid pharmacokinetics as a scientific field. Before his work, virtually nothing was known about how the human body processed THC — a compound that Mechoulam had isolated just eight years earlier.
What makes Lemberger's career trajectory remarkable is the through-line: he went from NIMH mapping how the body processes cannabis to Eli Lilly developing actual cannabis-derived medicine (Cesamet). The same pharmacokinetic expertise that produced the 11-OH-THC paper produced nabilone — a synthetic cannabinoid that proved cannabis compounds could be pharmaceutically useful, decades before Epidiolex made CBD mainstream.
“The pharmacology, disposition, and metabolism of 11-hydroxy-Δ9-THC mimic that of Δ9-THC, providing evidence that Δ9-THC is converted to the 11-hydroxy compound, with the latter compound being responsible for the observed effects.”
— Louis Lemberger, Robert Crabtree, Helen Rowe
National Institute of Mental Health, Bethesda, Maryland
A single sentence in Science that explained why edibles feel different — 50 years before most consumers learned the answer
Cite this study
Lemberger, Louis; Crabtree, Robert E; Rowe, Helen M. (1972). 11-hydroxy-Δ9-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. https://doi.org/10.1126/science.177.4043.62